Noninvasive Technologies for the Diagnosis of Coronary Artery Disease in Women
Noninvasive Technologies for the Diagnosis of Coronary Artery Disease in Women

Noninvasive Technologies for the Diagnosis of Coronary Artery Disease in Women


     0     
5
4
3
2
1



International Edition


About the Book

Cardiovascular disease is the leading cause of mortality for women in the U.S. Coronary heart disease-which includes coronary artery (or atherosclerotic) disease (CAD), myocardial infarction (MI), acute coronary syndromes, and angina-is the largest subset of this mortality. According to the American Heart Association (AHA), approximately one in three female adults has some form of cardiovascular disease. It is estimated that 8.1 million women alive today have a history of heart attack, angina pectoris (chest pain or discomfort caused by reduced blood supply to the heart muscle), or both, and experts predict that in 2010 alone an estimated 370,000 women will have a new or recurrent MI. Overall, women who have had an acute MI-particularly those older than 55 years of age-have a worse prognosis than men, with a greater recurrence of MI and higher mortality. More women (5.5 million) than men (4.3 million) have angina in total numbers. However, the prevalence of CAD in women with chest pain is about 50%, compared with 80% in men, which complicates diagnosis in women. The AHA suggests there is evidence showing that women at risk for CAD are less often referred for the appropriate diagnostic test than are men. Coronary anatomy and pathology have traditionally been defined and identified by invasive, catheter-based x-ray angiography, also referred to as coronary angiography. The major benefits of invasive coronary angiography over noninvasive techniques are that the use of a catheter makes it possible to see the coronary arteries with greater anatomic precision and resolution and to combine diagnosis and treatment in a single procedure. The limitations of the procedure include the invasive nature of the test and the limited data on the functional impact of a luminal obstruction. These limitations are generally considered to be minor when compared with the benefits of the procedure, and coronary angiography is now the reference (gold) standard for clinical care of patients who have chest pain suggestive of CAD. Coronary angiography, however, is not risk-free. Coronary angiography is generally indicated in patients who have chest pain and are at high risk for CAD. The goal of this comparative effectiveness report was to conduct a systematic review of the peer-reviewed medical literature assessing (1) the accuracy of different NITs for diagnosing CAD in women with symptoms suspicious of CAD, (2) the predictors affecting test accuracy, (3) the ability to provide risk stratification and prognostic information, inform decisionmaking about treatment options, and affect clinical outcomes, and (4) the safety concerns and risks to women undergoing these tests. The following Key Questions (KQs) were considered in this review: KQ1. What is the accuracy of one NIT in diagnosing obstructive and nonobstructive CAD when compared with another NIT or with coronary angiography in women with symptoms suspicious for CAD? KQ2. What are the predictors of diagnostic accuracy (e.g., age, race/ethnicity, body size, heart size, menopausal status, functional status, stress modality) of different NITs in women? KQ3. Is there evidence that the use of NITs (when compared with other NITs or with coronary angiography) in women improves: KQ3a. Risk stratification/prognostic information? KQ3b. Decisionmaking regarding treatment options (e.g., revascularization, optimal medical therapy)? KQ3c. Clinical outcomes (e.g., death, myocardial infarction, unstable angina, hospitalization, revascularization, angina relief, quality of life)? KQ4. Are there significant safety concerns/risks (i.e., radiation exposure, access site complications, contrast agent-induced nephropathy, nephrogenic systemic fibrosis, anaphylaxis, arrhythmias) associated with the use of different NITs to diagnose CAD in women with symptoms suspicious for CAD?


Best Sellers



Product Details
  • ISBN-13: 9781484094464
  • Publisher: Createspace Independent Publishing Platform
  • Publisher Imprint: Createspace Independent Publishing Platform
  • Height: 280 mm
  • No of Pages: 344
  • Series Title: English
  • Sub Title: Comparative Effectiveness Review Number 58
  • Width: 216 mm
  • ISBN-10: 1484094468
  • Publisher Date: 11 Apr 2013
  • Binding: Paperback
  • Language: English
  • Returnable: N
  • Spine Width: 18 mm
  • Weight: 847 gr


Add Photo
Add Photo

Customer Reviews

REVIEWS      0     
Click Here To Be The First to Review this Product
Noninvasive Technologies for the Diagnosis of Coronary Artery Disease in Women
Createspace Independent Publishing Platform -
Noninvasive Technologies for the Diagnosis of Coronary Artery Disease in Women
Writing guidlines
We want to publish your review, so please:
  • keep your review on the product. Review's that defame author's character will be rejected.
  • Keep your review focused on the product.
  • Avoid writing about customer service. contact us instead if you have issue requiring immediate attention.
  • Refrain from mentioning competitors or the specific price you paid for the product.
  • Do not include any personally identifiable information, such as full names.

Noninvasive Technologies for the Diagnosis of Coronary Artery Disease in Women

Required fields are marked with *

Review Title*
Review
    Add Photo Add up to 6 photos
    Would you recommend this product to a friend?
    Tag this Book Read more
    Does your review contain spoilers?
    What type of reader best describes you?
    I agree to the terms & conditions
    You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.

    CUSTOMER RATINGS AND REVIEWS AND QUESTIONS AND ANSWERS TERMS OF USE

    These Terms of Use govern your conduct associated with the Customer Ratings and Reviews and/or Questions and Answers service offered by Bookswagon (the "CRR Service").


    By submitting any content to Bookswagon, you guarantee that:
    • You are the sole author and owner of the intellectual property rights in the content;
    • All "moral rights" that you may have in such content have been voluntarily waived by you;
    • All content that you post is accurate;
    • You are at least 13 years old;
    • Use of the content you supply does not violate these Terms of Use and will not cause injury to any person or entity.
    You further agree that you may not submit any content:
    • That is known by you to be false, inaccurate or misleading;
    • That infringes any third party's copyright, patent, trademark, trade secret or other proprietary rights or rights of publicity or privacy;
    • That violates any law, statute, ordinance or regulation (including, but not limited to, those governing, consumer protection, unfair competition, anti-discrimination or false advertising);
    • That is, or may reasonably be considered to be, defamatory, libelous, hateful, racially or religiously biased or offensive, unlawfully threatening or unlawfully harassing to any individual, partnership or corporation;
    • For which you were compensated or granted any consideration by any unapproved third party;
    • That includes any information that references other websites, addresses, email addresses, contact information or phone numbers;
    • That contains any computer viruses, worms or other potentially damaging computer programs or files.
    You agree to indemnify and hold Bookswagon (and its officers, directors, agents, subsidiaries, joint ventures, employees and third-party service providers, including but not limited to Bazaarvoice, Inc.), harmless from all claims, demands, and damages (actual and consequential) of every kind and nature, known and unknown including reasonable attorneys' fees, arising out of a breach of your representations and warranties set forth above, or your violation of any law or the rights of a third party.


    For any content that you submit, you grant Bookswagon a perpetual, irrevocable, royalty-free, transferable right and license to use, copy, modify, delete in its entirety, adapt, publish, translate, create derivative works from and/or sell, transfer, and/or distribute such content and/or incorporate such content into any form, medium or technology throughout the world without compensation to you. Additionally,  Bookswagon may transfer or share any personal information that you submit with its third-party service providers, including but not limited to Bazaarvoice, Inc. in accordance with  Privacy Policy


    All content that you submit may be used at Bookswagon's sole discretion. Bookswagon reserves the right to change, condense, withhold publication, remove or delete any content on Bookswagon's website that Bookswagon deems, in its sole discretion, to violate the content guidelines or any other provision of these Terms of Use.  Bookswagon does not guarantee that you will have any recourse through Bookswagon to edit or delete any content you have submitted. Ratings and written comments are generally posted within two to four business days. However, Bookswagon reserves the right to remove or to refuse to post any submission to the extent authorized by law. You acknowledge that you, not Bookswagon, are responsible for the contents of your submission. None of the content that you submit shall be subject to any obligation of confidence on the part of Bookswagon, its agents, subsidiaries, affiliates, partners or third party service providers (including but not limited to Bazaarvoice, Inc.)and their respective directors, officers and employees.

    Accept

    New Arrivals



    Inspired by your browsing history


    Your review has been submitted!

    You've already reviewed this product!